My mom has stage 4 metastatic breast cancer and is on Zydus's Sigrima (a pertuzumab biosimilar). The hospital's package is: we pay ₹78,000 up front for the first dose, the next dose is free, and Vivitra (trastuzumab) comes free with every dose.
I looked through NPPA's revised MRP list to see if anything would help her.
None of the immunotherapy drugs show any significant change. Keytruda is still ₹2,16,500, and Opdyta, Tecentriq and Imfinzi are unchanged too.
The drugs that did drop, like palbociclib (₹40,421 → ₹2,720) and thiotepa (₹80,072 → ₹7,150), only fell because the old MRPs were inflated in the first place.
So is this a real saving for patients like my mom, or just fixing a number that was never real?